Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of mycobacterium abscessus

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1559-1563

  Maurer, Florian P ^a   Castelberg, Claudio ^a   Quiblier, Chantal ^a   Böttger, Erik C ^a   Somoskövi, Akos ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Drug susceptibility testing; Inducible resistance; Macrolides; Rapidly growing mycobacteria

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; METHYLASE ERM(41); METHYLTRANSFERASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CULTURE MEDIUM; MACROLIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ERM(41) GENE; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM MASSILIENSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL PROTEINS; CLARITHROMYCIN; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM;

EID: 84901208733     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku007     Document Type: Article

References (20)

1. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-99.
2. Liu P, Allaudeen H, Chandra R et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediaterelease regimen. Antimicrob Agents Chemother 2007; 51: 103-9.
3. Wilms EB, Touw DJ, Heijerman HG et al. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol 2012; 47: 658-65.
4. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
5. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
6. Wallace RJ Jr, Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-81.
7. Andini N, Nash KA. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother 2006; 50: 2560-2.
8. Nash KA. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Antimicrob Agents Chemother 2003; 47: 3053-60.
9. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-81.
10. Leao SC, Tortoli E, Euzeby JP et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-3.
11. Leao SC, Tortoli E, Viana-Niero C et al. Characterization ofmycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol 2009; 47: 2691-8.
12. Macheras E, Roux AL, Ripoll F et al. Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. J Clin Microbiol 2009; 47: 2596-600.
13. Kim HY, Kim BJ, Kook Y et al. Mycobacterium massiliense is differentiated fromMycobacteriumabscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54: 347-53.
14. Shallom SJ, Gardina PJ, Myers TG et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. J Clin Microbiol 2013; 51: 2943-9.
15. Brown BA, Wallace RJ Jr, Onyi GO et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-4.
16. Choi GE, Shin SJ, Won CJ et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917-25.
17. Adekambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003; 41: 5699-708.
18. Springer B, Stockman L, Teschner K et al. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. J Clin Microbiol 1996; 34: 296-303.
19. Maurer FP, Rüegger V, Ritter C et al. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother 2012; 67: 2606-11.
20. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.